Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

Details 詳細情報について

• CRID

  1363951793616440576

• DOI

  10.1016/j.diabet.2018.12.001

• ISSN

  12623636

• Web Site

  https://api.elsevier.com/content/article/PII:S1262363618302222?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1262363618302222?httpAccept=text/plain

• Data Source

  • Crossref